Patent intelligence · US
US 11680062
3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease
3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer…
Patent details — US 11680062
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 20, 2023
- Expiration
- Jun 15, 2043
- Applicant
- Northwest A & F University
- Claims
- 11
- CPC classes
- A61P, A61P25/28
Quick answer
US 11680062 (3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease) is held by Northwest A & F University. Status: granted. Granted Jun 20, 2023. Expires Jun 15, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Northwest A & F University
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P25/28
More from Northwest A & F University
Related pharmaceutical patents in our USPTO index.
-
US 12421280
Insulin like growth factor binding protein bioactive peptide fragments
granted -
US 12414995
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
granted -
US 12414981
JNK inhibitors for use in treating and preventing neurodegenerative disorders
granted -
US 12414963
Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin
granted -
US 12415995
Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
granted -
US 12409205
Nanomolecules for the treatment of inflammatory bowel diseases
granted -
US 12410474
Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient
granted -
US 12404533
Bioconjugate vaccines' synthesis in prokaryotic cell lysates
granted
Frequently asked questions
What is US patent 11680062?
US 11680062 (3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease) is held by Northwest A & F University. Status: granted. Granted Jun 20, 2023. Expires Jun 15, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11680062?
Northwest A & F University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 595 pharmaceutical patents for this assignee.
When does US 11680062 expire?
Our index shows an expiration date of Jun 15, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.